This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reisin, E. Articles by Hypertension, M. L. T. f. t. T. i. O. P. W. Search for Related Content PubMed PubMed Citation Articles by Reisin, E. Articles by Hypertension, M. L. T. f. t. T. i. O. P. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Obesity Hazardous Substances DB HYDROCHLOROTHIAZIDE LISINOPRIL

(Hypertension. 1997;30:140-145.)
© 1997 American Heart Association, Inc.

Articles

Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients

A Multicenter Placebo-Controlled Trial

Efrain Reisin; Matthew R. Weir; Bonita Falkner; Howard G. Hutchinson; Deborah A. Anzalone; Michael L. Tuck for the Treatment in Obese Patients With Hypertension; ; (TROPHY) Study Group

From Louisiana State University Medical Center, New Orleans (E.R.); University of Maryland Hospital, Baltimore (M.R.W.); Medical College of Pennsylvania, Philadelphia (B.F.); Zeneca Pharmaceuticals, Wilmington, Del (H.G.H., D.A.A.); and VA Medical Center, Sepulveda, Calif (M.L.T.).

Correspondence to Efrain Reisin, MD, LSUMC Medical Center, Section of Nephrology, 1542 Tulane Ave, New Orleans, LA 70112-2822.

Abstract Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (-8.3 and -7.7 versus -3.3 mm Hg, respectively; P<.005) and systolic (-9.2 and -10.0 versus -4.6 mm Hg, respectively; P<.05) pressures compared with placebo. Ambulatory blood pressure monitoring confirmed that lisinopril and hydrochlorothiazide effectively lowered 24-hour blood pressure compared with placebo (P<.001). Significant dose-response differences were observed between treatments. Sixty percent of patients treated with lisinopril had an office diastolic pressure <90 mm Hg compared with 43% of patients treated with hydrochlorothiazide (P<.05). Responses to therapies differed with both race and age. Neither treatment significantly affected insulin or lipid profiles; however, plasma glucose increased significantly after 12 weeks of hydrochlorothiazide therapy compared with lisinopril (+0.31 versus -0.21 mmol/L; P<.001). Hydrochlorothiazide also decreased serum potassium levels by 0.4 mmol/L from baseline. In conclusion, lisinopril was as effective as hydrochlorothiazide in treating obese patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors may show greater efficacy as monotherapy at lower doses compared with thiazide diuretics, may have a more rapid rate of response, and may offer advantages in patients at high risk of metabolic disorders.

Key Words: angiotensin-converting enzyme inhibitors • diuretics • hypertension, obesity

This article has been cited by other articles:

				I. Biaggioni Should We Target the Sympathetic Nervous System in the Treatment of Obesity-Associated Hypertension? Hypertension, February 1, 2008; 51(2): 168 - 171. [Full Text] [PDF]

				J. Jordan, S. Engeli, S. W. Boye, S. Le Breton, and D. L. Keefe Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension Hypertension, May 1, 2007; 49(5): 1047 - 1055. [Abstract] [Full Text] [PDF]

				M. Esler, N. Straznicky, N. Eikelis, K. Masuo, G. Lambert, and E. Lambert Mechanisms of Sympathetic Activation in Obesity-Related Hypertension Hypertension, November 1, 2006; 48(5): 787 - 796. [Full Text] [PDF]

				G. Dell'Omo, G. Penno, S. Del Prato, and R. Pedrinelli Chlorthalidone Improves Endothelial-Mediated Vascular Responses in Hypertension Complicated by Nondiabetic Metabolic Syndrome Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 265 - 272. [Abstract] [PDF]

				C. M Boustany, D. R. Brown, D. C. Randall, and L. A Cassis AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2005; 289(1): R181 - R186. [Abstract] [Full Text] [PDF]

				L. M. Brewster, G. A. van Montfrans, and J. Kleijnen Systematic Review: Antihypertensive Drug Therapy in Black Patients Ann Intern Med, October 19, 2004; 141(8): 614 - 627. [Abstract] [Full Text] [PDF]

				A. Ahmed Impact of ALLHAT on the Role of Angiotensin-Converting Enzyme Inhibitors in the Primary Prevention of Heart Failure Ann Intern Med, July 6, 2004; 141(1): W-9 - W-9. [Full Text] [PDF]

				A. M. Sharma Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension? Hypertension, July 1, 2004; 44(1): 12 - 19. [Abstract] [Full Text] [PDF]

				K. P. Davy and J. E. Hall Obesity and hypertension: two epidemics or one? Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R803 - R813. [Abstract] [Full Text] [PDF]

				A. A. da Silva, J. J. Kuo, L. S. Tallam, and J. E. Hall Role of Endothelin-1 in Blood Pressure Regulation in a Rat Model of Visceral Obesity and Hypertension Hypertension, February 1, 2004; 43(2): 383 - 387. [Abstract] [Full Text] [PDF]

				A. Aneja, F. El-Atat, S. I. McFarlane, and J. R. Sowers Hypertension and Obesity Recent Prog. Horm. Res., January 1, 2004; 59(1): 169 - 205. [Abstract] [Full Text]

				R. B. de Paula, A. A. da Silva, and J. E. Hall Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration Hypertension, January 1, 2004; 43(1): 41 - 47. [Abstract] [Full Text] [PDF]

				J. E. Hall The Kidney, Hypertension, and Obesity Hypertension, March 1, 2003; 41(3): 625 - 633. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Obesity, Hypertension, and Insulin Resistance Diabetes Care, November 1, 2002; 25(11): 2088 - 2097. [Full Text] [PDF]

				A. M. Sharma and S. Engeli Managing big issues on lean evidence: treating obesity hypertension Nephrol. Dial. Transplant., March 1, 2002; 17(3): 353 - 355. [Full Text] [PDF]

				Z. T. Bloomgarden Diabetes and Hypertension Diabetes Care, September 1, 2001; 24(9): 1679 - 1684. [Full Text] [PDF]

				A. M. Grandi, P. Zanzi, R. Broggi, A. Fachinetti, L. Guasti, L. Ceriani, and A. Venco Longitudinal Changes of Insulin Sensitivity in Essential Hypertension: Influence of Blood Pressure Control and Familial Predisposition to Hypertension J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3027 - 3031. [Abstract] [Full Text] [PDF]